^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Vertical inhibition of the MAPK pathway as potential treatment strategy in NRAS-mutant melanoma

Published date:
10/12/2022
Excerpt:
The combinatorial effects of mirdametinib with the pan-RAF dimer inhibitor lifirafenib or BGB-3245 were evaluated in a cohort of 14 primary and patient-derived melanoma cell lines harboring NRAS Q61 mutations....Results from this study showed significant therapeutic effects on NRAS Q61 mutated melanoma cell lines through combination of mirdametinib with either pan-RAF inhibitor both in vitro and in vivo….NRAS Q61 may serve as a prospective biomarker for patient stratification in trials assessing the combination of MEK and pan-RAF inhibitors in mutant melanoma.